U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H22O6
Molecular Weight 406.4279
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PALOMID 529

SMILES

COC1=CC=C(COC2=CC3=C(C=C2OC)C4=C(C=C(C=C4)C(C)O)C(=O)O3)C=C1

InChI

InChIKey=YEAHTLOYHVWAKW-UHFFFAOYSA-N
InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C24H22O6
Molecular Weight 406.4279
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

RES-529 (previously named Palomid 529, P529) is a phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) pathway inhibitor that interferes with the pathway through both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) dissociation. P529 inhibits tumor growth, angiogenesis, and vascular permeability. It retains the beneficial aspects of tumor vascular normalization that rapamycin boasts. This compound is currently being developed in oncology and ophthalmology. The oncology focus is for the treatment of glioblastoma, where it has received orphan designation by the US Food and Drug Administration, and prostate cancer.

CNS Activity

Curator's Comment: Palomid 529 penetrates the blood-brain barrier in mice. No human data available.

Approval Year

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.
2008 Nov 15
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
2011 Aug
Patents

Sample Use Guides

Five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. Mice were treated s.c. with 20 mg/kg Palomid 529 every 3 days.
Route of Administration: Other
Palomid 529 showed a potent antiproliferative activity in the NCI-60 cell lines panel, with growth inhibitory 50 (GI50) <35 microM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:59:24 GMT 2023
Edited
by admin
on Fri Dec 15 17:59:24 GMT 2023
Record UNII
XV9409EWG4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PALOMID 529
Common Name English
SG 00529
Code English
6H-DIBENZO(B,D)PYRAN-6-ONE, 8-(1-HYDROXYETHYL)-2-METHOXY-3-((4-METHOXYPHENYL)METHOXY)-
Systematic Name English
8-(1-HYDROXY-ETHYL)-2-METHOXY-3-(4-METHOXY-BENZYLOXY)-BENZO(C)CHROMEN-6-ONE
Systematic Name English
PALOMID-529
Code English
P-529
Code English
P529
Code English
SG-00529
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 463714
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
Code System Code Type Description
DRUG BANK
DB12812
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
PRIMARY
FDA UNII
XV9409EWG4
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID601026005
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
PRIMARY
PUBCHEM
11998575
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
PRIMARY
CAS
914913-88-5
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL2141712
Created by admin on Fri Dec 15 17:59:24 GMT 2023 , Edited by admin on Fri Dec 15 17:59:24 GMT 2023
PRIMARY